Inhibitors of Candida albicans Growth Transition
Author Information
Author(s): Midkiff John, Borochoff-Porte Nathan, White Dylan, Johnson Douglas I.
Primary Institution: University of Vermont
Hypothesis
The study investigates the efficacy of small molecules in inhibiting the budded-to-hyphal transition (BHT) in Candida albicans through various signaling pathways.
Conclusion
The study identifies several small molecules that can inhibit the budded-to-hyphal transition in Candida albicans, suggesting potential therapeutic applications.
Supporting Evidence
- The study identified 21 small molecules that could inhibit the C. albicans BHT.
- Chemical epistasis analyses suggested that most BHT inhibitors acted through the Efg1 or Cph1 pathways.
- Clozapine, an FDA-approved drug, was shown to inhibit the BHT by acting on the Gpr1 receptor.
Takeaway
Researchers found some drugs that can stop a yeast called Candida albicans from changing its shape, which is important for its growth and ability to cause infections.
Methodology
The study used various hyphal-inducing media to test the effects of 12 BHT inhibitors on Candida albicans growth.
Limitations
The study primarily focused on a limited number of signaling pathways and small molecules, which may not encompass all potential inhibitors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website